Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience

Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience

Abstract Background Despite all the scientific progress that has been made on understanding the disease, prognosis for patients with relapsed and refractory Hodgkin's lymphoma remains poor and the treatment is palliative in the majority of the cases. Thus, the aim of this study was to present...

Full description

Bibliographic Details
Main Authors: Talita Máira Bueno da Silveira da Rocha, Sergio Costa Fortier, Thais Rodrigues da Cunha Fischer, Guilherme Fleury Perini, Rafael Dezen Gaiolla, Laura Fogliatto, Marcia Torresan Delamain, Andressa Fragoso da Costa, Nelson Siqueira de Castro, Wolney Gois Barretos, Cármino Antonio de Souza, Valéria Buccheri, Carlos Sérgio Chiattone
Format: Article
Language:English
Published: Elsevier
Series:Revista Brasileira de Hematologia e Hemoterapia
Subjects:
Everolimus
Hodgkin's lymphoma
Refractory
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842017000300216&lng=en&tlng=en

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842017000300216&lng=en&tlng=en

Similar Items